There is growing global concern regarding the rise of antibiotic-resistant organisms. Many of these reports have focused on various Gram-positive and Gram-negative pathogens, with little attention to the genus Ureaplasma. Ureaplasma spp. are associated with numerous infectious diseases affecting pregnant women, neonates and the immunocompromised. Treatment options are extremely limited due to high levels of intrinsic resistance resulting from the unique physiology of these organisms and further restricted in cases of the developing fetus or neonate, often limiting therapeutic options to predominantly macrolides or rarely fluoroquinolones. The increasing presence of macrolide-and fluoroquinolone-resistant strains among neonatal infections may result in pan-drug resistance and potentially untreatable conditions. Here, we review the requirements for accurate measurement of antimicrobial susceptibility, provide a comprehensive review of the antimicrobial resistance (AMR) for Ureaplasma species in the literature and contextualize these results relative to some investigators' reliance on commercial kits that are not CLSI compliant when determining AMR. The dramatic variation in the resistance patterns and impact of high levels of AMR amongst neonatal populations suggests the need for continued surveillance. Commercial kits represent an excellent tool for initial antibiotic susceptibility determination and screening. However, AMR reporting must utilize internationally standardized methods, as high-titre samples, or Mycoplasma hominis-contaminated samples routinely give false AMR results. Furthermore, there is a requirement for future reports to determine the underlying AMR mechanisms and determine whether expanding AMR is due to spontaneous mutation, transmission of resistance genes on mobile elements or selection and expansion of resistant clones.
Introduction: Ureaplasma as a pathogen
A focus on the ESKAPE pathogens, MDR Mycobacterium tuberculosis and drug-resistant Neisseria gonorrhoeae predominates both the scientific literature and the media, with little attention drawn to some of the less prominent pathogens. This relative lack of attention does not correlate to the absence of a problem. Ureaplasma are some of the smallest self-replicating organisms known to inhabit the human host. As the name suggests, they possess a unique capacity to utilize urea as a primary carbon source in the generation of ATP. 1 Within the genus, two human-associated species exist: Ureaplasma parvum and Ureaplasma urealyticum, which predominantly differ in their genomic coding capacity (0.7520.78 versus 0.8420.95 Mbp genomes).
2 Ureaplasma spp. have had a controversial history as a pathogen, in part due to the high colonization rate among healthy individuals with 40% -80% of healthy females being colonized. Ureaplasma are now recognized pathogens among pregnant females, neonates, sexually active individuals and the immunocompromised. 3, 4 One of the most recent reports has identified a link between individuals suffering from hyperammonaemia following lung transplantation and systemic infection by Ureaplasma spp. 5 
Therapeutic options
Treatment of Ureaplasma spp. infections is complicated by high levels of intrinsic resistance to many commonly prescribed antimicrobials. For example, the lack of a cell wall confers resistance to all b-lactam and glycopeptide antibiotics whereas the lack of de novo synthesis of folic acid renders cells resistant to sulphonamides and diaminopyrimidines.
Only four classes of antibiotics are recognized for the treatment of Ureaplasma infections. These are notably those that belong to the fluoroquinolone, tetracycline, chloramphenicol and macrolide classes. When considering infections among pregnant females or neonates, the number of therapeutic options is further restricted due to accumulation of tetracyclines in developing bones, 'grey baby syndrome' associated with chloramphenicol and reticence in using fluoroquinolones in neonates. Therefore, the emergence of macrolide-resistant strains threatens to severely limit treatment of Ureaplasma infections among these individuals, especially as Ureaplasma fluoroquinolone resistance is present and expanding in Europe. 6 Administration of antibiotics has been associated with both clinical and microbiological cure in clinical presentations. In a study by Bharat et al., 5 resolution of hyperammonaemia was correlated with administration of azithromycin or levofloxacin resulting in subsequent microbiological cure. In a single case, the patient did not respond to azithromycin treatment, but this was later attributed to the presence of a macrolide-resistant strain. In some instances, chloramphenicol has been used in the treatment of Ureaplasma-induced meningitis among both adults and neonates, although potential complications surrounding toxicity in systemic use need to be balanced with clinical outcome. 7, 8 Although favourable results have been noted in many studies, the use of antibiotics among individuals with suspected nongonococcal urethritis (NGU) as a result of Ureaplasma spp. infection is still questionable. A study by Khosropour et al. 9 noted that 57% of individuals with NGU who were infected with Ureaplasma spp. and received antimicrobial therapy with initially azithromycin (1 g) followed by doxycycline (100 mg twice daily for 7 days), or vice versa, were still colonized after 6 weeks of therapy.
These data suggest that in many cases it is possible to manage infections caused by Ureaplasma when dealing with antibioticsusceptible strains. As highlighted by this Review, antibioticresistant strains of Ureaplasma are present within the community. The mechanisms of resistance vary according to the antibiotic in question. Accumulation of point mutations in the 23S rRNA genes and the quinolone resistance-determining regions of the parC gene are the predominant mechanisms of resistance to macrolides and fluoroquinolones, respectively, with acquisition of the gene encoding the Tet(M) ribosomal protection protein on the Tn916-like mobile element being associated with resistance to tetracycline. 6 The detailed mechanisms of resistance are beyond the scope of this Review.
Determining antibiotic susceptibility profiles for Ureaplasma spp. isolates using CLSI guidelines and commercially available kits Routine antimicrobial susceptibility testing (AST) for Ureaplasma is rarely performed due to its fastidious nature and specialized growth medium requirements. Therefore, most infections are treated empirically, utilizing molecular methods for test of cure. For this reason, AST is predominantly conducted for surveillance purposes, in the development of novel antimicrobials or in clinical cases where patients fail to respond to treatment. 10 AST has been reported for Ureaplasma over numerous decades. In 2001, the publication Cumitech 34 outlined not only diagnostic methods for ureaplasmas and mycoplasmas, but also detailed standardized methods for AST. However, in 2011, an international collaboration to standardize AST for Ureaplasma spp., Mycoplasma hominis and Mycoplasma pneumoniae was published by the CLSI. CLSI M43-A highlights the requirement for standardized media (10B broth or A8 agar), quality control isolates [U. urealyticum (SV9) ATCC w 33175 TM in the case of Ureaplasma] and reference ranges for determining susceptibility or resistance.
Although standardized methodologies exist, there is still a lack of routine AST. One factor that may contribute to the lack of routine AST may be the complex nature of testing regimes. Ureaplasmas are unable to grow as confluent lawns on bacteriological agar plates, which negates the use of commonly used disc diffusion assays; therefore, broth microdilution and agar dilution methods are favoured, although these have their drawbacks. The inability to grow Ureaplasma to a turbid culture, owing to the self-toxic nature of metabolites produced as well as the small cell size, means that McFarland standards are not available for standardizing inoculum size. Broth culture methods can utilize an increase in pH in the medium, which increases from pH¼ 6.5 to pH .8.0 caused by the conversion of urea to ammonium ions by Ureaplasma, changing the phenol red in the medium from yellow orange to cerise red. To achieve the 10 4 -10 5 cfu/mL inoculum required for reliable susceptibility testing, cultures require predetermination of cfu prior to AST, with freezing of the culture of known inoculum so that numbers can be adjusted accordingly. This can be a lengthy process, which delays the reporting of an isolate's antibiogram. Routine clinical laboratories cannot feasibly accommodate performing these methods, even if the complex routine medium can be obtained commercially: it is too labour intensive and requires specialized training of staff. This is where the commercially available Ureaplasma AST kits find their niche.
Commercial kits provide a streamlined and simple approach to the detection of Ureaplasma spp. and AST. These kits contain dried antibiotic powders at two breakpoint concentrations that become reconstituted upon inoculation. Although these kits can be sourced from a range of suppliers, caution must be exercised when interpreting the results because there are a number of factors that do not comply with the approved CLSI guidelines. First, none of these kits utilizes a dilution method to accurately quantify the inoculum that is added to the test panel. Although some kits have separate wells that can differentiate inoculum levels of ≥10 4 cfu/specimen, they utilize an undisclosed method of inhibition as no physical dilution prior to addition to these wells occurs in the sample preparation (Table 1) . It is well established that a load .10 5 will give a false-resistant result. 6 For example, the Mycoplasma IST2 has a well which indicates the inoculum meets or exceeds 10 4 cfu/mL (minimum required for CLSI). However the assay does not indicate when the inoculum is .10 5 cfu/mL (it can be as high as 10 7 cfu/mL), which routinely yields false-resistant growth results by overwhelming the small amount of antibiotic in the well. 11 Second, commercial kits cannot separate results for Ureaplasma and M. hominis mixed cultures. 12 Owing to the intrinsic resistance of M. hominis to macrolides, it is impossible to determine whether Ureaplasma spp. in these mixed samples are susceptible to macrolides. 13 This has led to the unfortunate false resistance reporting by investigators that note higher rates of macrolide resistance among sample with coisolation of both organisms, 12 as they did not do follow-up investigations on Ureaplasma isolates purified from the M. hominis contamination. For reliable susceptibility testing, it is essential to isolate a purified culture of the test isolate.
The most important shortfall in the commercial AST kits is the use of test concentrations different from the CLSI-determined breakpoints. Interpretation guidance provided with these kits give three outcomes: (i) red identification well (Ureaplasma, Mycoplasma or both) with all others yellow¼ susceptible isolate; (ii) red identification well (Ureaplasma, Mycoplasma or both) with lower antibiotic concentration red but higher concentration yellow¼intermediate susceptibility isolate; and (iii) red identification well with both antibiotic concentration wells red=antibiotic-resistant isolate. Unfortunately, the concentrations in many of these kits do not match those defined by CLSI documentation: CLSI designates the erythromycin resistance breakpoint as growth at ≥16 mg/L erythromycin, whereas the bioMé rieux kit utilizes 4 mg/L, 4-fold below the accepted threshold. This may lead to 331 Review JAC over-reporting of macrolide resistance among studies that have utilized the Mycoplasma IST2 kit, a topic that is discussed later. Conversely, the CLSI-designated tetracycline resistance breakpoint is 2 mg/L whereas the lower and higher Mycoplasma IST2 concentrations are 4 and 8 mg/L, respectively. Although this may suggest the possibility of under-reporting of tetracycline resistance among clinical isolates, it is unlikely as Tet(M)-mediated resistance results in high MIC values .32 mg/L. Exceptions to this have been noted in the situations of phenotypically susceptible strains which are tet(M) positive, but are only resistant following induction with antibiotic. 14, 15 This anomaly would be missed by both commercial and CLSI-approved protocols. With respect to testing for fluoroquinolone resistance, there are again inconsistencies with the CLSI protocol. The primary concern for Mycoplasma IST2 kits is the low threshold for ciprofloxacin breakpoints at 2 mg/L. The CLSI guidelines do not define a resistance breakpoint for ofloxacin or ciprofloxacin; however, the CLSI resistance breakpoints for the more recent fluoroquinolones levofloxacin (third generation) and moxifloxacin (fourth generation), which have greater efficacy than the older fluoroquinolones, are ≥4 mg/ L. Therefore, it is not surprising that investigators utilizing the Mycoplasma IST2 kit report high levels of ciprofloxacin-specific resistance and in-depth investigation subsequently determined that these isolates are actually susceptible when re-tested under CLSI compliant conditions. 15 
Evaluation of studies reporting antibiotic resistance
Antibiotic resistance is recognized as an international issue whereby resistant strains can be imported from countries with high levels of resistance. For this reason, we carried out a review of the literature from the past 10 years (2006-16) to identify the number of studies examining resistance among Ureaplasma spp. From this, we identified 33 reports on clinical antibiotic resistance among Ureaplasma from a collection of single case reports as well as larger studies. 6,8,12,14 -43 From these reports, we extracted data regarding the year of publication, country in which the study was conducted, the patient group examined, methods by which AST was determined, whether the species of Ureaplasma was determined, number of isolates examined and finally, where relevant, the percentage of reported isolates resistant to the antibiotics stated (Table 2) .
We identified, as expected, that rates of resistance varied by country and in some instances noted dramatic differences in reports from within the same country. For example, a study by Huang et al.
12 from 2016 examined 1951 individuals in Xiangya, China and identified 54% to be resistant to erythromycin. This is in contrast to the work by Song et al. 40 and Ye et al., 39 who examined 1513 and 15 594 individuals in Hangzhou, China with much lower rates of resistance at 11% and 1%, respectively. In some instances, resistance was high to only a single class of antibiotic. For example, a study by Leli et al. 29 found high levels of ofloxacin resistance (27.6%) among 152 Ureaplasma isolated in Italy, whereas no resistance to any tetracycline or macrolide antibiotics was detected. The highest levels of fluoroquinolone resistance were documented in countries such as China with figures of 53% of isolates resistant to ofloxacin and 88% of isolates resistant to levofloxacin. 12, 39 Resistance to tetracyclines was noted at high rates in South Africa (73% of isolates), 38 the USA (34% of isolates) 27 and Cuba (31% isolates). 34 Many of these isolates were additionally confirmed as possessing the tet(M) mobile genetic element. Of greatest concern in relation to the treatment of neonatal infection are the high reported levels of macrolide resistance seen in certain countries. Using erythromycin as the indicator for resistance, as suggested by the CLSI, the highest levels of resistance were seen in Hungary (85%), 26 South Africa (80%), 38 Turkey (54%), 18 China (54%), 12 Israel (46%) 25 and Cuba (46%). 34 Although these percentages are high in relation to countries such as the UK (0% -2%) or Croatia (0% -7%), there is a real possibility of clonal strains being introduced from countries with high rates of resistance to those with low rates. Alternatively, these reported levels may be an over-representation as a result of the inaccuracies of commercial assays as described previously. Use of the broth microdilution technique was as prevalent as the use of the Mycoplasma IST2 kit (10/33 studies and 12/33 studies, respectively). However, as discussed earlier, there are numerous limitations to commercial kits such as the Mycoplasma IST2, e.g. the incorporation of breakpoint levels that do not agree with CLSI guidelines. This may have resulted in the over-reporting of resistance for some antibiotics.
Although Ureaplasma have been recognized as two separate species since 2000, there is still a lack of discrimination at the species level. Many of the diagnostic methods used in the literature reviewed report only the presence of Ureaplasma and do not differentiate to the species level, partly due to culture-based commercial kits, and in some instances report U. urealyticum by 
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Review default due to historical taxonomic reasons. This reporting style has a negative impact on surveillance and understanding the distribution of resistant species as well as understanding the role of the two species in the clinical outcome. For example, the association between Ureaplasma and NGU has been controversial, but studies that have looked at Ureaplasma as two independent species have shown that U. urealyticum is significantly associated with NGU (adjusted OR 2.3) as compared with U. parvum (adjusted OR 0.4). 44 Nucleic acid technologies exist whereby species can be differentiated and these should be adopted for any future reporting. 45 The role of commercial kits in a clinical setting While the available commercial kits for M. hominis and Ureaplasma spp. detection and AST (in their current formats) may not provide publishable antibiotic resistance data without follow-up investigation, these kits provide an ideal method to investigate these emerging pathogens in a busy clinical setting. Urethritis is a common condition that is usually sexually acquired and commonly classified into those caused by N. gonorrhoeae infection or other causes. The 2015 UK national guidelines on the management of NGU, published by the Clinical Effectiveness Group of the British Association for Sexual Health and HIV, list ureaplasmas as one of the most common causes (11% -26%) of NGU in men, surpassed only by Chlamydia trachomatis (11%-50%) and Mycoplasma genitalium (6% -50%). 46 Based on the guidelines, the first-line treatment in outpatient clinics is azithromycin (single dose of 1 g) or doxycycline (100 mg/day for 7 days). These treatments were demonstrated to have similar efficacy in the past (75% and 69%, respectively) against ureaplasmas; 47, 48 however, inadvertent treatment of ureaplasmas is likely to decline with increasing global emergence of antimicrobial resistance. Furthermore, there is increasing evidence that treatment with a single 1 g azithromycin dose drives the development of mutations in the 23S RNA gene, resulting in macrolide antimicrobial resistance in M. genitalium, 49 -51 which would likely also develop in the closely related ureaplasmas, and this may contribute to the failure of first-line therapy to treat up to 25% of patients. Treatment of these recurrent urethritis patients requires multiple follow-up appointments and the infection may persist for up to 1 month with empirical treatment involving up to four different antibiotics (macrolides, doxycycline, metronidazole and fluoroquinolones) before it resolves.
In the clinical setting, commercial kits provide reliable, sensitive detection in 24 -48 h and give important guidance for therapeutic treatment in resistant infection. Furthermore, they require no specialist equipment, reagents or training. Scrutiny of the commercial kits in Table 1 identifies the Myco Well D-One as the only one that utilizes the CLSI breakpoints for antibiotic concentrations, and it additionally identifies Gardnerella vaginalis, Trichomonas vaginalis and Candida albicans (all relevant to common genitourinary clinical investigation). The advantage of this particular kit is that titration of the microbial load by traditional methods for any positive sample, to ensure the inoculum tested was 10 4 cfu, would ensure that the results were performed under CLSI-compliant guidelines and therefore the results could be published. Ureaplasmas are also emerging pathogens in other clinical settings: development of bronchopulmonary dysplasia (or chronic lung disease) in premature neonates; 52 presence as the sole organism identified in histologically confirmed chorioamnionitis of moderate/late pre-term and term placentae; 4 underlying cause of fatal hyperammonaemia in lung transplant patients; 5 wound infection or abscess formation in kidney transplant patients; 53, 54 and meningitis in adults. 8 Therefore, simple commercial kits that detect ureaplasmas and direct therapy may find expanding utility in clinical settings outside genitourinary medicine.
Concluding remarks
This Review has highlighted the need for continual surveillance in order to keep track of resistance patterns. Commercial kits are an easy method for initial screening, but indication of resistance needs to be followed up appropriately, not just reported. From this, we suggest the following recommendations: (i) if a mixed M. hominis and Ureaplasma spp. culture is identified, isolation of single Ureaplasma colonies and repeat AST are required in order to obtain reliable data for macrolide resistance; (ii) confirm resistance according to approved CLSI guidelines including quantifying the inoculum; and/or (iii) determine the underlying mechanism of resistance. While it is tempting to attribute the low antibiotic resistance rates in some countries, such as the UK, to vigilance in prescribing polices and prudent use, the geographic differential in antibiotic resistance is unlikely to be maintained, particularly with the degree of travel between countries with high and low levels of resistance in combination with the increased prescribing of macrolide antibiotics for N. gonorrhoeae, C. trachomatis and M. genitalium infections. While commercial kits offer simple and rapid clinical guidance for patient treatment, it is no longer acceptable to use these kits to report international antibiotic resistance trends for Ureaplasma infection. Scientific rigor now requires additional investigation: either molecular identification of known resistance mechanisms or retesting positive patient samples with CLSI-compliant AST methodology.
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